Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 401–500 of 1,001
Yuan, J., Ng, W. H., Lam, P. Y. P., Wang, Y., Xia, H., Yap, J., Guan, S. P., Lee, A. S. G., Wang, M., Baccarini, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0365-2 · Cited by 57
Oncogenic transformation and experimental models of human cancer
Anna, C. S. (2007) · Frontiers in bioscience · doi:10.2741/2661 · Cited by 63
Costello syndrome and related disorders
Quezada, E., & Gripp, K. W. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3282f161dc · Cited by 58
Linardou, H., Briasoulis, E. C., Dahabreh, I. J., Mountzios, G., PAPADIMITRIOU, C. A., Papadopoulos, S., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.008 · Cited by 56
Kocián, P., Šedivcová, M., Drgáč, J., Černá, K., Hoch, J., Kodet, R., Bartůňková, J., Špíšek, R., & Fialová, A. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.07.312 · Cited by 54
Liu, R., Zhang, W., Liu, Z., & Zhou, H. (2017) · BMC Genomics · doi:10.1186/s12864-017-3761-z · Cited by 54
Leung, E. L., Luo, L. X., Liu, Z. Q., Wong, V. K. W., Lu, L., Xie, Y., Zhang, N., Qu, Y. Q., Fan, X., Li, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0065-9 · Cited by 60
Sharma, S. B., Lin, C., Farrugia, M. K., McLaughlin, S. L., Ellis, E. J., Brundage, K. M., Salkeni, M. A., & Ruppert, J. M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00480-14 · Cited by 63
Differential dynamics of RAS isoforms in GDP- and GTP-bound states
Kapoor, A., & Travesset, A. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24805 · Cited by 53
Wey, M., Lee, J., Jeong, S. S., Kim, J., & Heo, J. (2013) · Biochemistry · doi:10.1021/bi400679q · Cited by 60
Interplay between Menin and K-Ras in Regulating Lung Adenocarcinoma
Wu, Y., Feng, Z.-J., Gao, S.-B., Matkar, S. S., Xu, B., Duan, H., Lin, X., Li, S.-H., Hua, X., & Jin, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382416 · Cited by 53
Grasso, D., Garcia, M. N., Hamidi, T., Cano, C. E., Calvo, E. L., Lomberk, G. A., Urrutia, R. A., & Iovanna, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.74 · Cited by 55
PAF-Mediated MAPK Signaling Hyperactivation via LAMTOR3 Induces Pancreatic Tumorigenesis
Jun, S., Lee, S., Kim, H.-C., Ng, C., Schneider, A. M., Ji, H. L., Ying, H., Wang, H., DePinho, R. A., & Park, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.026 · Cited by 76
Lima, J. P. D. S. N., Georgieva, M., Haaland, B. A., & Lopes, G. D. L., Jr. (2017) · Cancer Medicine · doi:10.1002/cam4.1001 · Cited by 59
Subramonian, D., Phanhthilath, N., Rinehardt, H., Flynn, S. M., Huo, Y., Zhang, J., Messer, K. S., Mo, Q., Huang, S., Lesperance, J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0905-8 · Cited by 52
The Notch pathway: hair graying and pigment cell homeostasis.
Schouwey, K., & Beermann, F. (2008) · PubMed · doi:10.14670/hh-23.609 · Cited by 58
SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions
Bénéteau, C., Cavé, H., Moncla, A., Dorison, N., Münnich, A., Verloès, A., & Leheup, B. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.44 · Cited by 54
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
Caiola, E., Salles, D. C., Frapolli, R., Lupi, M., Rotella, G., Ronchi, A., Garassino, M. C., Mattschas, N. A. L., Colavecchio, S., Broggini, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5019 · Cited by 52
Cogoi, S., Shchekotikhin, A. E., Membrino, A., Sinkevich, Y. B., & Xodo, L. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3019063 · Cited by 52
Shen, Z., Qin, X., Yan, M., Li, R., Chen, G., Zhang, J., & Chen, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13609 · Cited by 52
Targeted Therapy for Medullary Thyroid Cancer: A Review
Priya, S. R., Dravid, C. S., Digumarti, R., & Dandekar, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00238 · Cited by 58
RAS signalling in energy metabolism and rare human diseases
Dard, L., Bellancé, N., Lacombe, D., & Rossignol, R. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.05.003 · Cited by 62
Upadhyaya, M., Spurlock, G., Thomas, L. E., Thomas, N. S. T., Richards, M., Mautner, V.-F., Cooper, D. N., Guha, A., & Yan, J. S. (2012) · Human Mutation · doi:10.1002/humu.22044 · Cited by 56
Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics
Gnad, F., Young, A. E., Zhou, W., Lyle, K. S., Ong, C. C., Stokes, M. P., Silva, J. C., Belvin, M. P., Friedman, L. S., Koeppen, H., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.027052 · Cited by 54
Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 59
Horn, S., Bergholz, U., Jücker, M., McCubrey, J. A., Trümper, L. H. P., Stocking, C., & Bäsecke, J. (2008) · Oncogene · doi:10.1038/onc.2008.40 · Cited by 51
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Lin, C., Lin, J.-K., Lin, T.-C., Chen, W.-S., Yang, S.-H., Wang, H.-S., Lan, Y., Jiang, J., Yang, M., & Chang, S. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23675 · Cited by 54
RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance
Ray, H., Roméo, Y., Lavoie, G., Déléris, P., Tcherkezian, J., Galan, J. A., & Roux, P. P. (2012) · Oncogene · doi:10.1038/onc.2012.472 · Cited by 54
Lessons from computer simulations of Ras proteins in solution and in membrane
Prakash, P., & Gorfe, A. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.07.024 · Cited by 58
Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
Frank, S. B., & Miranti, C. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00273 · Cited by 66
MicroRNAs targeting EGFR signalling pathway in colorectal cancer
Mlčochová, J., Vychytilova‐Faltejskova, P., Němeček, R., Svoboda, M., & Slabý, O. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1470-9 · Cited by 50
Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton
O’Neill, G. M., Stehn, J. R., & Gunning, P. W. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.08.004 · Cited by 51
Essential Role of Cdc42 in Ras-Induced Transformation Revealed by Gene Targeting
Stengel, K. R., & Zheng, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037317 · Cited by 52
Mordant, P., Loriot, Y., Leteur, C., Caldéraro, J., Bourhis, J., Wislez, M., Soria, J., & Deutsch, É. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1014 · Cited by 52
Šolman, M., Ligabue, A., Blaževitš, O., Jaiswal, A., Zhou, Y., Hong, L., Lectez, B. L. P., Kopra, K., Guzmán, C., Härmä, H., et al. (2015) · eLife · doi:10.7554/elife.08905 · Cited by 52
Chen, J., Wang, L., Wang, W., Sun, H., Pang, L., & Bao, H. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104639 · Cited by 49
Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis
Yang, M., Govern, C. C., Chakraborty, A. K., Hartzell, C., Ksionda, O., Lemmens, E., Coakley, K. M., Dail, M., Harvey, R. C., Bakker, J., et al. (2012) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 49
Self-citationVirgilio, A., Sinisi, A., Russo, V., Gerardo, S., Adriano, S., Galeone, A., Taglialatela‐Scafati, O., & Roperto, F. P. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b01937 · Cited by 49
Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
Naramura, M., Nadeau, S. A., Mohapatra, B. C., Ahmad, G., Mukhopadhyay, C., Sattler, M., Raja, S. M., Natarajan, A., Band, V., & Band, H. (2011) · Oncotarget · doi:10.18632/oncotarget.233 · Cited by 53
MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E
Trejo, C. L., Juan, J., Vicent, S., Sweet-Cordero, A., & McMahon, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3649 · Cited by 49
Duhamel, S., Hébert, J., Gaboury, L. A., Bouchard, A., Simon, R., Sauter, G., Basik, M., & Meloche, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2126 · Cited by 53
Germline expression of H‐RasG12V causes neurological deficits associated to Costello syndrome
Viosca, J., Schuhmacher, A. J., Guerra, C. E., & Barco, Á. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2008.00443.x · Cited by 51
Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells
Koul (2009) · International Journal of Oncology · doi:10.3892/ijo_00000285 · Cited by 49
Edmonson, M. N., Patel, A., Hedges, D. J., Wang, Z., Rampersaud, E., Kesserwan, C. A., Zhou, X., Liu, Y., Newman, S., Rusch, M., et al. (2019) · Genome Research · doi:10.1101/gr.250357.119 · Cited by 54
“Figure 5 shows a germline NRAS G12S variant detected in one patient to illustrate this case.”
BackgroundHähnel, P. S., Enders, B., Sasca, D., Roos, W. P., Kaina, B., Bullinger, L., Theobald, M., & Kindler, T. (2014) · Blood · doi:10.1182/blood-2013-01-477620 · Cited by 52
Zeng, L., Li, J., Wang, Y., Qian, C., Chen, Y., Zhang, Q., Wu, W., Zhong, L., Liang, J., Shuai, X., et al. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.08.007 · Cited by 52
Molecular Insight in Gastric Cancer Induction: An Overview of Cancer Stemness Genes
Akhavan‐Niaki, H., & Samadani, A. A. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9749-7 · Cited by 48
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 54
Vujic, I., Sanlorenzo, M., Esteve‐Puig, R., Vujic, M., Kwong, A., Tsumura, A., Murphy, R. M., Moy, A., Posch, C., Itzinger-Monshi, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6907 · Cited by 54
Membrane orientation dynamics of lipid-modified small GTPases
Prakash, P., & Gorfe, A. A. (2016) · Small GTPases · doi:10.1080/21541248.2016.1211067 · Cited by 53
Hereditary myeloid malignancies
Rafei, H., & Dinardo, C. D. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.001 · Cited by 51
Califano, R., Abidin, A. Z., Tariq, N.-U.-A., Economopoulou, P., Metro, G., & Mountzios, G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.009 · Cited by 49
“most growth factor receptors, including EGFR and ALK [25].”
BackgroundDiet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis
Ramadori, G., Konstantinidou, G., Venkateswaran, N., Biscotti, T., Morlock, L., Galiè, M., Williams, N. S., Luchetti, M. M., Santinelli, A., Scaglioni, P. P., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.11.020 · Cited by 53
Lahti, S. J., Xing, M., Zhang, D., Lee, J. J., Magnetta, M. J., & Kim, H. S. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.05.032 · Cited by 48
Watanabe, T., Yoshino, T., Uetake, H., Yamazaki, K., Ishiguro, M., Kurokawa, T., Saijo, N., Ohashi, Y., & Sugihara, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt062 · Cited by 46
Vignola, M. J., Kashatus, D. F., Taylor, G. A., Counter, C. M., & Valdivia, R. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103010 · Cited by 46
Chen, X., Makarewicz, J., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2013) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 49
KRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
Addissie, Y. A., Kotecha, U. H., Hart, R. A., Martinez, A. F., Kruszka, P. S., & Muenke, M. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37259 · Cited by 49
Differential Regulation of RasGAPs in Cancer
Grewal, T., Köse, M., Tebar, F., & Enrich, C. (2011) · Genes & Cancer · doi:10.1177/1947601911407330 · Cited by 56
KRAS Engages AGO2 to Enhance Cellular Transformation
Shankar, S., Pitchiaya, S., Malik, R., Kothari, V., Hosono, Y., Yocum, A. K., Gundlapalli, H., White, Y., Firestone, A., Cao, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.034 · Cited by 46
Self-citationNussinov, R., Zhang, M., Tsai, C., Liao, T.-J., Fushman, D., & Jang, H. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0461-0 · Cited by 50
“KRasG12V/E37G prefers RA domaincontaining proteins such as NORE1A more than other mutants (Chang et al. 2014; Schubbert et al. 2007; Vandal et al. 2014).”
BackgroundPei, X., Dai, Y., Youssefian, L. E., Chen, S., Bodie, W. W., Takabatake, Y., Felthousen, J. G., Almenara, J. A., Kramer, L. B., Dent, P., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339432 · Cited by 47
Targeting oncogenic Ras: Figure 1.Preprint
Díaz-Flores, E., & Shannon, K. (2007) · Genes & Development · doi:10.1101/gad.1587907 · Cited by 48
“Somatic RAS mutations are highly prevalent in many human cancers that respond poorly to current treatments, including carcinomas of the lung, pancreas, and colon; melanoma; and myeloid leukemia (for review, see Schubbert et al. 2007).”
BackgroundSelf-citationSpencer-Smith, R., Terrell, E. M., Insinna, C., Agamasu, C., Wagner, M. E., Ritt, D. A., Stauffer, J., Stephen, A. G., & Morrison, D. K. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.10.016 · Cited by 42
Chakraborty, J., Chakraborty, S., Chakraborty, S., & Narayan, M. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194988 · Cited by 53
Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization
Tommasi, S., Zheng, A., Weninger, A., Bates, S. E., Li, X. A., Wu, X., Hollstein, M., & Besaratinia, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1051 · Cited by 45
Ras-Induced Changes in H3K27me3 Occur after Those in Transcriptional Activity
Hosogane, M., Funayama, R., Nishida, Y., Nagashima, T., & Nakayama, K. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003698 · Cited by 51
Ono, R., Kumagai, H., Nakajima, H., Hishiya, A., Taki, T., Horikawa, K., Takatsu, K., Satoh, T. K., Hayashi, Y., Kitamura, T., et al. (2009) · Leukemia · doi:10.1038/leu.2009.177 · Cited by 45
Fast simultaneous detection of K-RASmutations in colorectal cancer
Chang, Y., Yeh, K., Chang, T., Chai, C., Lu, H., Hsu, N. C.-H., & Chang, J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-179 · Cited by 45
Khaidakov, M., & Mehta, J. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046973 · Cited by 46
PIK3CA, HRAS and KRAS Gene Mutations in Human Penile Cancer
Andersson, P., Kolaric, A., Windahl, T., Kirrander, P., Söderkvist, P., & Karlsson, M. G. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.12.040 · Cited by 45
Statins can modulate effectiveness of antitumor therapeutic modalities
Jakóbisiak, M., & Gołąb, J. (2009) · Medicinal Research Reviews · doi:10.1002/med.20162 · Cited by 52
Qian, F., Xiao, J., Gai, L., & Zhu, J. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22944 · Cited by 46
“K-Ras was initially supposed to mainly activate Raf-MAPK cascades, eventually leading to the phosphorylation and activation of MAPK substrates, a large part of which are oncogenic transcription factors and could directly drive the proliferation, invasion, and chemoresistance of cancer cells.(26) However, studies in re…”
BackgroundNeoantigens in Hematologic Malignancies
Biernacki, M. A., & Bleakley, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00121 · Cited by 50
Molecular Mechanism of Autophagy and Its Regulation by Cannabinoids in Cancer
Lee, X. C., Werner, E., & Falasca, M. (2021) · Cancers · doi:10.3390/cancers13061211 · Cited by 50
Ashton‐Beaucage, D., Lemieux, C., Udell, C. M., Sahmi, M., Rochette, S., & Therrien, M. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002539 · Cited by 50
Integrated analysis of RNA-binding proteins in human colorectal cancer
Fan, X., Liu, L., Shi, Y., Guo, F., Wang, H., Zhao, X., Zhong, D., & Li, G. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01995-5 · Cited by 46
“RAS oncogene activation mutations are commonly seen in colon cancer [8].”
BackgroundGene regulatory networks in disease and ageing
Avila, P. U., Padvitski, T., Leote, A. C., Chen, H., Sáez-Rodríguez, J., Kann, M., & Beyer, A. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00849-7 · Cited by 57
“In addition to contributing to cancer phenotypes, germline variants can cause rare diseases by changing signalling networks 52 .”
Bianconi, F., Baldelli, E., Ludovini, V., Crinò, L., Flacco, A., & Valigi, P. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.010 · Cited by 54
Schlaeth, M., Berger, S., Derer, S., Klausz, K., Lohse, S., Dechant, M., Lazar, G. A., Schneider‐Merck, T., Peipp, M., & Valerius, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01505.x · Cited by 54
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
Tran, P. T., Bendapudi, P. K., Lin, H. J., Choi, P. S., Koh, S., Chen, J., Horng, G., Hughes, N. P., Schwartz, L. H., Miller, V. A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002018 · Cited by 45
Yeddula, N., Xia, Y., Ke, E., Beumer, J., & Verma, I. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520110112 · Cited by 43
Mosaicism in Cutaneous Disorders
Lim, Y. H., Moscato, Z. M., & Choate, K. A. (2017) · Annual Review of Genetics · doi:10.1146/annurev-genet-121415-121955 · Cited by 48
TLE4 promotes colorectal cancer progression through activation of JNK/c-Jun signaling pathway
Wang, S., Gao, K., Deng, D., Cai, J., Xiao, Z., He, L., Jiao, H., Ye, Y., Yang, R., Li, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6694 · Cited by 45
Missing heritability: paternal age effect mutations and selfish spermatogonia
Goriely, A., & Wilkie, A. O. M. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2809-c1 · Cited by 43
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis
Zhao, Z., Chen, C.-C., Rillahan, C. D., Shen, R., Kitzing, T. M., McNerney, M. E., Díaz-Flores, E., Zuber, J. A., Shannon, K., Beau, M. M. L., et al. (2015) · Nature Genetics · doi:10.1038/ng.3251 · Cited by 46
Self-citationChristian, S. L., Zu, D., Licursi, M., Komatsu, Y., Pongnopparat, T., Codner, D., & Hirasawa, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044267 · Cited by 50
Sample preparation and analytical strategies for large-scale phosphoproteomics experiments
Kanshin, E., Michnick, S. W., & Thibault, P. (2012) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2012.05.005 · Cited by 52
“somatic gain-of-function mutations n RAS genes [5]), defects in negative regulatory mechanisms (e.”
BackgroundGremer, L., Luca, A. D., Merbitz-Zahradnik, T., Dallapiccola, B., Morlot, S., Tartaglia, M., Kutsche, K., Ahmadian, M. R., & Rosenberger, G. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp548 · Cited by 48
Neurofibromatosis type 1: diagnosis and recent advances
Upadhyaya, M. (2010) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2010.494660 · Cited by 45
Yang, J., Mitra, A., Dojer, N., Fu, S., Rowicka, M., & Brasier, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt493 · Cited by 44
Tsubaki, M., Fujiwara, D., Takeda, T., Kino, T., Tomonari, Y., Itoh, T., Imano, M., Satou, T., Sakaguchi, K., & Nishida, S. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12690 · Cited by 45
The Interplay between Oncogenic Signaling Networks and Mitochondrial Dynamics
Nagdas, S., & Kashatus, D. F. (2017) · Antioxidants · doi:10.3390/antiox6020033 · Cited by 49
Jang, J.-Y., Lee, Y.-S., Jeon, Y., Lee, K., Jang, J., & Kim, C.-W. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.1 · Cited by 45
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 50
“These pathways stimulate critical cellular activities, including cell differentiation, proliferation, and survival of extracellular stimuli [4,5].”
Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild‐type GISTs
Martinho, O., Gouveia, A., Viana‐Pereira, M., Silva, P., Pimenta, A. P. A., Reis, R. M., & Lopes, J. M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03323.x · Cited by 45
Nussinov, R., Tsai, C., Muratcioğlu, S., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1100079 · Cited by 45
“K-Ras interacts with more RA domain-containing proteins (including RIN, RIN2, Nore1, RASSF1, RGL, RGL2) than other mutants.[17,151,152] The differential effector binding selectivity reflects the altered conformational landscape.”
Wang, Z., Guo, Q., Wang, R., Xu, G., Li, P., Sun, Y., She, X., Liu, Q., Chen, Q., Yu, Z., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0355-1 · Cited by 46
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.